Alan P Kozikowski

This inventor holds 88 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Histone Deacetylase Inhibitors (CPC class A61K45-06). Top assignees: Georgetown University, University of Illinois, Mars, Incorporated. Active years: 1990-2026.

USPTO Granted Patents = 88 (Patent Applications = 13)

% Patents Active = 67.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 2.6

ph-index = 13

Forward Citations = 862(Granted Patents)

Forward Citations (Not Self Cited) = 782(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Ponte Verda Beach, FL (US) (1991 - 1993)
Ponte Verde Beach, FL (US) (1993)
Ponte Vedra Beach, FL (US) (1993)
Ponte Vedre Beach, FL (US) (1992 - 1995)
Pittsburgh, PA (US) (1990 - 1999)
Arlington, VA (US) (2010)
Princeton, NJ (US) (1996 - 2013)
Chicago, IL (US) (2006 - 2024)

Company Filing History:

33 out of 496

Georgetown University

patents

21 out of 2,420

University of Illinois

Mayo Foundation for Medical Education and Research

patents

5. 6 out of 1,957

University of Pittsburgh

patents

6. 4 out of 311

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

7. 3 out of 282

The George Washington University

patents

8. 2 out of 6

Fidia-Georgetown Institute for the Neurosciences

patents

9. 2 out of 3,794

Johns Hopkins University

patents

10. 2 out of 299

The Children's Hospital of Philadelphia

patents

11. 2 out of 961

The University of Chicago

patents

12. 2 out of 1,324

The University of North Carolina at Chapel Hill

patents

13. 1 out of 3

Biostream Therapeutics, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

16. 1 out of 1,049

The University of Arizona

patents

17. 4 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1990-2026

Loading Chart...

Areas of Expertise:

Histone Deacetylase Inhibitors

RAD51 Inhibitors

Selective Receptor Agonists

Isoxazole Hydroxamic Acids

Therapeutic Methods

5-HT(2C) Receptor

Nrf Activators

HIF Activators

CNS Injury Treatments

Ligands

GSK3 Inhibitors

Polyphenols

88 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12522572 - Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors (2026-01-13),

2. 12024493 - Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors (2024-07-02),

3. 11739064 - HDAC inhibitors and therapeutic methods using the same (2023-08-29),

4. 11472780 - Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors (2022-10-18),

5. 10973819 - Small molecules inhibitors of RAD51 (2021-04-13),

6. 10934255 - Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same (2021-03-02),

7. 10912761 - Methods and compositions involving RAD51 inhibitors (2021-02-09),

8. 10836733 - HDAC inhibitors and therapeutic methods using the same (2020-11-17),

9. 10456394 - Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors (2019-10-29),

10. 10407381 - Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists (2019-09-10),

11. 10227295 - Selective histone deactylase 6 inhibitors (2019-03-12),

12. RE47009 - HDAC inhibitors and therapeutic methods using the same (2018-08-27),

13. 9956192 - Selective histone deactylase 6 inhibitors (2018-05-01),

14. 9751832 - Selective histone deactylase 6 inhibitors (2017-09-05),

15. 9409858 - Selective histone deactylase 6 inhibitors (2016-08-09),

Title: Innovator Spotlight: Alan P Kozikowski

Introduction:

Alan P Kozikowski, a prolific inventor based in Princeton, NJ, has made significant contributions to the field of pharmacology with a remarkable portfolio of 55 patents. His groundbreaking work includes novel compounds and formulations targeting metabotropic glutamate receptors and NAALADase enzymes, paving the way for advancements in disease treatment and imaging technology.

Latest Patents:

Kozikowski's latest patents focus on two key areas of innovation. The first patent involves the development of ligands for metabotropic glutamate receptors and inhibitors of NAALADase. These compounds offer novel therapeutic opportunities for modulating receptor activity and treating diseases associated with abnormalities in these enzymes. The second patent centers around imaging agents labeled with radioisotopes for visualizing tissues expressing NAALADase and PSMA, presenting new avenues for diagnostic imaging and targeted therapies.

Career Highlights:

Throughout his career, Kozikowski has been affiliated with esteemed institutions such as Georgetown University and Mars, Incorporated. His expertise in pharmacology and drug development has positioned him as a leading figure in the industry, driving forward cutting-edge research and development initiatives.

Collaborations:

Kozikowski has collaborated closely with notable peers in the field, including Gian Luca Araldi and Werner Tueckmantel. These collaborations have played a pivotal role in advancing his research efforts and achieving significant milestones in the realm of pharmacological innovations.

Conclusion:

In conclusion, Alan P Kozikowski stands out as a trailblazing inventor whose work has had a profound impact on the field of pharmacology. His dedication to pushing the boundaries of innovation and his unwavering commitment to improving healthcare outcomes underscore his exceptional contributions to the scientific community.